DrugPatentWatch Database Preview
Sorafenib tosylate - Generic Drug Details
What are the generic sources for sorafenib tosylate and what is the scope of sorafenib tosylate freedom to operate?
Sorafenib tosylate
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.There are thirteen drug master file entries for sorafenib tosylate. One supplier is listed for this compound.
Summary for sorafenib tosylate
| US Patents: | 8 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 13 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 81 |
| Clinical Trials: | 158 |
| Patent Applications: | 6 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for sorafenib tosylate |
| DailyMed Link: | sorafenib tosylate at DailyMed |
Pharmacology for sorafenib tosylate
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Protein Kinase Inhibitors |
Synonyms for sorafenib tosylate
| 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonate) |
| 1-(4-chloro-3-(Trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonic acid) |
| 1-(4-chloro-3-(Trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulphonate) |
| 1-(4-chloro-3-(Trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulphonic acid) |
| 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-, mono(4-methylbenzenesulfonate) |
| 207S591 |
| 3(S),10(R)-OH-octadeca-6-trans-4,12-cis-trienoate |
| 3(S),10(R)-OH-Octadeca-6-trans-4,12-cis-trienoic acid |
| 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide 4-methylbenzenesulfonate |
| 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide tosylate |
| 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N2-methylpyridine-2-carboxamide mono (4-methylbenzenesulfonate) |
| 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate |
| 4-[4-[[[4-chloro-3-(trifluoromethyl)anilino]-oxomethyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-methylbenzenesulfonic acid |
| 4-[4-[[4-chloranyl-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-methylbenzenesulfonic acid |
| 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-methylbenzenesulfonic acid |
| 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide;4-methylbenzenesulfonic acid |
| 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide tosylate |
| 4-{4-[({[4-Chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N -methylpyridine-2-carboxamide tosylate |
| 4-{4-[({[4-Chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide tosylate |
| 4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy} -pyridine-2-carboxylic acid methylamide-4-methylbenzenesulfonate |
| 4-{4-[3-(4-Cl-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide 4-methylbenzenesulfonate |
| 4-methylbenzolsulfons |
| 475207-59-1 |
| 5T62Q3B36J |
| A20368 |
| A819449 |
| AB0044027 |
| ABP000935 |
| AC-6799 |
| AC1L8QVY |
| AC1Q5GRN |
| AK162385 |
| AKOS015924650 |
| AKOS027469919 |
| AM20090612 |
| AOB87366 |
| AT-17079 |
| BAY 43-9006 mono-p-tosylate |
| BAY 43-9006 tosylate |
| BAY 54-9085 |
| BAY 54-9085Sorafenib tosylATE |
| BAY 54-9085Sorafenib tosylic acid |
| BAY-54-9085 |
| BAY43-9006 mono-p-tosylate |
| BCP0726000112 |
| C28H24ClF3N4O6S |
| CAS-475207-59-1 |
| CCG-208000 |
| CHEBI:50928 |
| CHEMBL1200485 |
| CS-0164 |
| D06272 |
| DSSTox_CID_27817 |
| DSSTox_GSID_47839 |
| DSSTox_RID_82581 |
| DTXSID9047839 |
| FT-0650737 |
| FT-0698449 |
| HE072572 |
| HE344612 |
| HMS2219E08 |
| HMS3654I09 |
| HY-10201A |
| IVDHYUQIDRJSTI-UHFFFAOYSA-N |
| KS-000006NB |
| LS-186598 |
| MFCD08235032 |
| MLS002415564 |
| MolPort-006-705-989 |
| NCGC00167488-01 |
| NCGC00167488-08 |
| ND-0228 |
| Nexavar (TN) |
| Nexavar(R) |
| NSC-724772 |
| NSC724772 |
| para-toluene sulfonate sorafenib tosylate |
| PubChem22488 |
| Q-1222 |
| Q-201729 |
| Q812 |
| RL03773 |
| S-8502 |
| s1040 |
| SMR001339079 |
| Sorafenib - Nexavar |
| Sorafenib (BAY-43-9006) |
| Sorafenib (Tosylate) |
| Sorafenib tosilate |
| Sorafenib tosilate (JAN) |
| Sorafenib tosilic acid |
| Sorafenib tosylate (USAN) |
| Sorafenib tosylate [USAN] |
| Sorafenib Tosylate(Bay 43-9006)/ |
| Sorafenib TsOH salt |
| Sorafenib, p-Toluenesulfonate salt |
| SORAFENIB; TOLUENESULFONIC ACID |
| SR-00000000529 |
| SR-00000000529-5 |
| ST24049296 |
| Tox21_112489 |
| Tox21_112489_1 |
| UNII-5T62Q3B36J |
US Patents and Regulatory Information for sorafenib tosylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for sorafenib tosylate
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Africa | 200702510 | ➤ Sign Up |
| Ukraine | 93673 | ➤ Sign Up |
| Hong Kong | 1209620 | ➤ Sign Up |
| Tunisia | SN07341 | ➤ Sign Up |
| Tunisia | SN00010 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for sorafenib tosylate
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2006008 | Lithuania | ➤ Sign Up | PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719 |
| C 031/2006 | Ireland | ➤ Sign Up | SPC 031/2006: 20070528, EXPIRES: 20210718 |
| 0242 | Netherlands | ➤ Sign Up | |
| 2006008,C1140840 | Lithuania | ➤ Sign Up | PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719 |
| C/GB07/004 | United Kingdom | ➤ Sign Up | PRODUCT NAME: SORAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/06/342/001 20060721 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: